

# Clio P Mavragani

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6326539/publications.pdf>

Version: 2024-02-01

124  
papers

3,890  
citations

126907

33  
h-index

133252

59  
g-index

124  
all docs

124  
docs citations

124  
times ranked

3887  
citing authors

#	ARTICLE	IF	CITATIONS
1	The geoepidemiology of Sjögren's syndrome. <i>Autoimmunity Reviews</i> , 2010, 9, A305-A310.	5.8	246
2	Type I and II interferon signatures in Sjogren's syndrome pathogenesis: Contributions in distinct clinical phenotypes and Sjogren's related lymphomagenesis. <i>Journal of Autoimmunity</i> , 2015, 63, 47-58.	6.5	215
3	Sjögren's Syndrome. <i>Annual Review of Pathology: Mechanisms of Disease</i> , 2014, 9, 273-285.	22.4	198
4	Activation of the type I interferon pathway in primary Sjogren's syndrome. <i>Journal of Autoimmunity</i> , 2010, 35, 225-231.	6.5	165
5	Expression of Long Interspersed Nuclear Element 1 Retroelements and Induction of Type I Interferon in Patients With Systemic Autoimmune Disease. <i>Arthritis and Rheumatology</i> , 2016, 68, 2686-2696.	5.6	149
6	Augmented interferon- $\alpha$ pathway activation in patients with Sjögren's syndrome treated with etanercept. <i>Arthritis and Rheumatism</i> , 2007, 56, 3995-4004.	6.7	140
7	Predicting the risk for lymphoma development in Sjogren syndrome. <i>Medicine (United States)</i> , 2016, 95, e3766.	1.0	137
8	Sjögren syndrome. <i>Cmaj</i> , 2014, 186, E579-E586.	2.0	135
9	Cardiovascular disease in systemic lupus erythematosus: A comprehensive update. <i>Journal of Autoimmunity</i> , 2017, 82, 1-12.	6.5	132
10	The management of Sjögren's syndrome. <i>Nature Clinical Practice Rheumatology</i> , 2006, 2, 252-261.	3.2	110
11	B-cell activating factor genetic variants in lymphomagenesis associated with primary Sjogren's syndrome. <i>Journal of Autoimmunity</i> , 2014, 51, 89-98.	6.5	99
12	Sjögren's syndrome: Old and new therapeutic targets. <i>Journal of Autoimmunity</i> , 2020, 110, 102364.	6.5	79
13	Association of the response to tumor necrosis factor antagonists with plasma type I interferon activity and interferon- $\alpha$ / $\beta$ ratios in rheumatoid arthritis patients: A post hoc analysis of a predominantly Hispanic cohort. <i>Arthritis and Rheumatism</i> , 2010, 62, 392-401.	6.7	77
14	Predicting the Outcome of Sjogren's Syndrome-Associated Non-Hodgkin's Lymphoma Patients. <i>PLoS ONE</i> , 2015, 10, e0116189.	2.5	77
15	Lymphotoxin-beta receptor blockade reduces CXCL13 in lacrimal glands and improves corneal integrity in the NOD model of Sjögren's syndrome. <i>Arthritis Research and Therapy</i> , 2011, 13, R182.	3.5	71
16	Mechanisms and New Strategies for Primary Sjögren's Syndrome. <i>Annual Review of Medicine</i> , 2017, 68, 331-343.	12.2	68
17	Defective regulation of L1 endogenous retroelements in primary Sjogren's syndrome and systemic lupus erythematosus: Role of methylating enzymes. <i>Journal of Autoimmunity</i> , 2018, 88, 75-82.	6.5	65
18	Endocrine alterations in primary Sjogren's syndrome: An overview. <i>Journal of Autoimmunity</i> , 2012, 39, 354-358.	6.5	64

#	ARTICLE	IF	CITATIONS
19	Subclinical atherosclerosis and impaired bone health in patients with primary Sjogren's syndrome: prevalence, clinical and laboratory associations. <i>Arthritis Research and Therapy</i> , 2015, 17, 99.	3.5	64
20	Fatigue in Primary Sjogren's Syndrome: Clinical, Laboratory, Psychometric, and Biologic Associations. <i>Arthritis Care and Research</i> , 2016, 68, 123-131.	3.4	64
21	Sjogren's Syndrome: Autoantibodies to Cellular Antigens. <i>International Archives of Allergy and Immunology</i> , 2000, 123, 46-57.	2.1	63
22	Conventional Therapy of Sjogren's Syndrome. <i>Clinical Reviews in Allergy and Immunology</i> , 2007, 32, 284-291.	6.5	61
23	A BAFF Receptor His159Tyr Mutation in Sjogren's Syndrome-Related Lymphoproliferation. <i>Arthritis and Rheumatology</i> , 2015, 67, 2732-2741.	5.6	60
24	Low disease activity—irrespective of serologic status at baseline—associated with reduction of corticosteroid dose and number of flares in patients with systemic lupus erythematosus treated with belimumab: A real-life observational study. <i>Seminars in Arthritis and Rheumatism</i> , 2018, 48, 467-474.	3.4	59
25	B-cell activating factor and related genetic variants in lupus related atherosclerosis. <i>Journal of Autoimmunity</i> , 2018, 92, 87-92.	6.5	51
26	Adult-Onset Still's Disease: From Pathophysiology to Targeted Therapies. <i>International Journal of Inflammation</i> , 2012, 2012, 1-10.	1.5	48
27	New advances in the classification, pathogenesis and treatment of Sjogren's syndrome. <i>Current Opinion in Rheumatology</i> , 2013, 25, 623-629.	4.3	48
28	Activation of the type I interferon pathway in primary Sjogren's syndrome. <i>Current Opinion in Rheumatology</i> , 2011, 23, 459-464.	4.3	46
29	Primary Sjogren's Syndrome of Early and Late Onset: Distinct Clinical Phenotypes and Lymphoma Development. <i>Frontiers in Immunology</i> , 2020, 11, 594096.	4.8	45
30	Psychopathological and personality features in primary Sjogren's syndrome—associations with autoantibodies to neuropeptides. <i>Rheumatology</i> , 2010, 49, 1762-1769.	1.9	43
31	Elevated IgG4 Serum Levels Among Primary Sjogren's Syndrome Patients: Do They Unmask Underlying IgG4-Related Disease?. <i>Arthritis Care and Research</i> , 2014, 66, 773-777.	3.4	42
32	Clinical and Laboratory Predictors of Distinct Histopathological Features of Lupus Nephritis. <i>Medicine (United States)</i> , 2015, 94, e829.	1.0	42
33	Primary versus Secondary Sjogren Syndrome: Is It Time To Reconsider These Terms?. <i>Journal of Rheumatology</i> , 2019, 46, 665-666.	2.0	38
34	Emerging roles for chemokines and cytokines as orchestrators of immunopathology in Sjogren's syndrome. <i>Rheumatology</i> , 2021, 60, 3072-3087.	1.9	36
35	Myositis autoantibody profiles and their clinical associations in Greek patients with inflammatory myopathies. <i>Clinical Rheumatology</i> , 2019, 38, 125-132.	2.2	35
36	Association Between DNA Damage Response, Fibrosis and Type I Interferon Signature in Systemic Sclerosis. <i>Frontiers in Immunology</i> , 2020, 11, 582401.	4.8	34

#	ARTICLE	IF	CITATIONS
37	Adverse events and infections in patients with rheumatoid arthritis treated with conventional drugs or biologic agents: a real world study. <i>Clinical and Experimental Rheumatology</i> , 2015, 33, 216-24.	0.8	32
38	Contribution of Genetic Factors to Sjögren's Syndrome and Sjögren's Syndrome Related Lymphomagenesis. <i>Journal of Immunology Research</i> , 2015, 2015, 1-12.	2.2	31
39	Effective DNA damage response after acute but not chronic immune challenge: SARS-CoV-2 vaccine versus Systemic Lupus Erythematosus. <i>Clinical Immunology</i> , 2021, 229, 108765.	3.2	29
40	MTHFR gene variants and non-MALT lymphoma development in primary Sjögren's syndrome. <i>Scientific Reports</i> , 2017, 7, 7354.	3.3	28
41	Atherosclerosis: Beyond the lipid storage hypothesis. The role of autoimmunity. <i>European Journal of Clinical Investigation</i> , 2020, 50, e13195.	3.4	28
42	Contribution of MTHFR gene variants in lupus related subclinical atherosclerosis. <i>Clinical Immunology</i> , 2018, 193, 110-117.	3.2	25
43	Increased frequency of the PTPN22W* variant in primary Sjogren's Syndrome: Association with low type I IFN scores. <i>Clinical Immunology</i> , 2016, 173, 157-160.	3.2	24
44	TNFAIP3 F127C Coding Variation in Greek Primary Sjogren's Syndrome Patients. <i>Journal of Immunology Research</i> , 2018, 2018, 1-8.	2.2	24
45	A biomarker for lymphoma development in Sjogren's syndrome: Salivary gland focus score. <i>Journal of Autoimmunity</i> , 2021, 121, 102648.	6.5	24
46	Antibodies against citrullinated alpha enolase peptides in primary Sjogren's syndrome. <i>Clinical Immunology</i> , 2017, 183, 300-303.	3.2	21
47	COVID-19 infection among autoimmune rheumatic disease patients: Data from an observational study and literature review. <i>Journal of Autoimmunity</i> , 2021, 123, 102687.	6.5	19
48	TREX1 variants in Sjogren's syndrome related lymphomagenesis. <i>Cytokine</i> , 2020, 132, 154781.	3.2	18
49	TLR7 Signaling Drives the Development of Sjögren's Syndrome. <i>Frontiers in Immunology</i> , 2021, 12, 676010.	4.8	18
50	Increased Prevalence of Antibodies to Thyroid Peroxidase in Dry Eyes and Mouth Syndrome or Sicca Asthenia Polyalgia Syndrome. <i>Journal of Rheumatology</i> , 2009, 36, 1626-1630.	2.0	17
51	Increased Serum Type I Interferon Activity in Organ-Specific Autoimmune Disorders: Clinical, Imaging, and Serological Associations. <i>Frontiers in Immunology</i> , 2013, 4, 238.	4.8	17
52	Type I interferonopathy in a young adult. <i>Rheumatology</i> , 2017, 56, 2241-2243.	1.9	17
53	Activation of type I interferon in systemic lupus erythematosus. <i>Expert Review of Clinical Immunology</i> , 2007, 3, 579-588.	3.0	16
54	Brief Report: Adrenal autoimmunity in primary Sjögren's syndrome. <i>Arthritis and Rheumatism</i> , 2012, 64, 4066-4071.	6.7	16

#	ARTICLE	IF	CITATIONS
55	Type I and II Interferon Signatures Can Predict the Response to Anti-TNF Agents in Inflammatory Bowel Disease Patients: Involvement of the Microbiota. <i>Inflammatory Bowel Diseases</i> , 2020, 26, 1543-1553.	1.9	16
56	Type I interferon signature in Sjögren's syndrome: pathophysiological and clinical implications. <i>Clinical and Experimental Rheumatology</i> , 2019, 37 Suppl 118, 185-191.	0.8	16
57	Genetic contributors and soluble mediators in prediction of autoimmune comorbidity. <i>Journal of Autoimmunity</i> , 2019, 104, 102317.	6.5	15
58	Hypertension: An immune related disorder?. <i>Clinical Immunology</i> , 2020, 212, 108247.	3.2	15
59	Adenosine-to-inosine RNA editing contributes to type I interferon responses in systemic sclerosis. <i>Journal of Autoimmunity</i> , 2021, 125, 102755.	6.5	14
60	Prevalence and spectrum of symptomatic pulmonary involvement in primary Sjögren's syndrome. <i>Clinical and Experimental Rheumatology</i> , 2018, 36 Suppl 112, 94-101.	0.8	14
61	Independent association of low IFN $\gamma$ 1 gene expression and type I IFN score/IFN $\gamma$ 1 ratio with obstetric manifestations and triple antiphospholipid antibody positivity in primary antiphospholipid syndrome. <i>Clinical Immunology</i> , 2019, 209, 108265.	3.2	13
62	Multicenter Cross-sectional Study of Patients with Rheumatoid Arthritis in Greece: Results from a cohort of 2.491 patients. <i>Mediterranean Journal of Rheumatology</i> , 2018, 29, 27-37.	0.8	13
63	Sicca syndrome following immune checkpoint inhibition. <i>Clinical Immunology</i> , 2020, 217, 108497.	3.2	12
64	Lymphoma in Sjögren's Syndrome: Predictors and Therapeutic Options. <i>Current Treatment Options in Rheumatology</i> , 2020, 6, 1-17.	1.4	12
65	Is polydipsia sometimes the cause of oxcarbazepine-induced hyponatremia?. <i>European Journal of Internal Medicine</i> , 2005, 16, 296-297.	2.2	11
66	Retroperitoneal fibrosis and c-ANCA positivity. <i>Clinical Rheumatology</i> , 2007, 26, 115-116.	2.2	11
67	Tongue Atrophy in Sjögren Syndrome Patients with Mucosa-associated Lymphoid Tissue Lymphoma: Autoimmune Epithelitis beyond the Epithelial Cells of Salivary Glands?. <i>Journal of Rheumatology</i> , 2018, 45, 1565-1571.	2.0	11
68	Anxiety and Extraversion in Lupus-Related Atherosclerosis. <i>Frontiers in Psychiatry</i> , 2018, 9, 246.	2.6	10
69	Atherosclerosis in SLE: a potential role for serum parathormone levels. <i>Lupus Science and Medicine</i> , 2020, 7, e000393.	2.7	10
70	Hematological Abnormalities in COVID-19 Disease: Association With Type I Interferon Pathway Activation and Disease Outcomes. <i>Frontiers in Medicine</i> , 2022, 9, 850472.	2.6	10
71	Pure red cell aplasia in a Sjögren's syndrome/lupus erythematosus overlap patient. <i>American Journal of Hematology</i> , 2003, 72, 259-262.	4.1	9
72	Expression of APOBEC family members as regulators of endogenous retroelements and malignant transformation in systemic autoimmunity. <i>Clinical Immunology</i> , 2021, 223, 108649.	3.2	9

#	ARTICLE	IF	CITATIONS
73	Interferon (IFN)-stimulated gene 15: A novel biomarker for lymphoma development in Sjögren's syndrome. <i>Journal of Autoimmunity</i> , 2021, 123, 102704.	6.5	9
74	Sjögren's Syndrome: Recent Updates. <i>Journal of Clinical Medicine</i> , 2022, 11, 399.	2.4	9
75	B cells and atherosclerosis in systemic lupus erythematosus. <i>Expert Review of Clinical Immunology</i> , 2019, 15, 417-429.	3.0	8
76	Combined seronegativity in Sjögren's syndrome. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 80-84.	0.8	8
77	Leukocyte Immunoglobulin-Like Receptor A3 (LILRA3): A Novel Marker for Lymphoma Development among Patients with Young Onset Sjögren's Syndrome. <i>Journal of Clinical Medicine</i> , 2021, 10, 644.	2.4	7
78	Cutaneous ulcers: An unusual manifestation of inherited thrombophilia. <i>American Journal of Hematology</i> , 2004, 76, 139-142.	4.1	6
79	Linear IgA dermatosis in a patient with primary Sjögren's syndrome. <i>Rheumatology</i> , 2013, 52, 403-404.	1.9	6
80	Predictors of renal histopathology in antineutrophil cytoplasmic antibody associated glomerulonephritis. <i>Journal of Autoimmunity</i> , 2016, 72, 57-64.	6.5	6
81	Stress and Disease Onset in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. <i>Frontiers in Psychiatry</i> , 2017, 8, 286.	2.6	6
82	Lipoprotein-Associated Phospholipase A2: A Novel Contributor in Sjögren's Syndrome-Related Lymphoma?. <i>Frontiers in Immunology</i> , 2021, 12, 683623.	4.8	6
83	Type I interferon detection in autoimmune diseases: challenges and clinical applications. <i>Expert Review of Clinical Immunology</i> , 2021, 17, 883-903.	3.0	6
84	Ill-defined neurological syndromes with autoimmune background: a diagnostic challenge. <i>Journal of Rheumatology</i> , 2007, 34, 341-5.	2.0	6
85	COVID-19: Clinical features and outcomes in unvaccinated 2-dose and 3-dose vaccinated against SARS-CoV-2 patients with systemic autoimmune and autoinflammatory rheumatic diseases. <i>Journal of Autoimmunity</i> , 2022, 131, 102846.	6.5	6
86	Osteoprotegerin and MTHFR gene variations in rheumatoid arthritis: association with disease susceptibility and markers of subclinical atherosclerosis. <i>Scientific Reports</i> , 2022, 12, .	3.3	6
87	Clinical Significance of Higher Cutoffs for Myositis Autoantibody Positivity Using the Euroimmun Research Line Blot: Comment on the Article by Mecoli et al. <i>Arthritis and Rheumatology</i> , 2020, 72, 1042-1044.	5.6	5
88	+3179G/A Insulin-Like Growth Factor-1 Receptor Polymorphism: A Novel Susceptibility Contributor in Anti-Ro/SSA Positive Patients with Sjögren's Syndrome: Potential Clinical and Pathogenetic Implications. <i>Journal of Clinical Medicine</i> , 2021, 10, 3960.	2.4	5
89	Autoantibodies to ox-LDL in Sjögren's syndrome: are they atheroprotective?. <i>Clinical and Experimental Rheumatology</i> , 2018, 36 Suppl 112, 61-67.	0.8	5
90	Genetic Variants of the BAFF Gene and Risk of Fatigue Among Patients With Primary Sjögren's Syndrome. <i>Frontiers in Immunology</i> , 2022, 13, 836824.	4.8	5

#	ARTICLE	IF	CITATIONS
91	Biologics in Sjögren's syndrome. <i>Pharmacological Research</i> , 2019, 147, 104389.	7.1	4
92	Predicting Lymphoma Development by Exploiting Genetic Variants and Clinical Findings in a Machine Learning-Based Methodology With Ensemble Classifiers in a Cohort of Sjögren's Syndrome Patients. <i>IEEE Open Journal of Engineering in Medicine and Biology</i> , 2020, 1, 49-56.	2.3	4
93	Musculoskeletal Manifestations in Sjögren's Syndrome: An Orthopedic Point of View. <i>Journal of Clinical Medicine</i> , 2021, 10, 1574.	2.4	4
94	Study of the incidence of osteoporosis in patients with Sjögren's syndrome (pSS) and investigation of activation of the RANKL / RANK and osteoprotegerin (OPG) system. <i>Mediterranean Journal of Rheumatology</i> , 2018, 29, 224-227.	0.8	4
95	Eosinophilic Fasciitis following Checkpoint Inhibitor Therapy with Pembrolizumab. <i>Mediterranean Journal of Rheumatology</i> , 2021, 32, 376.	0.8	4
96	Sjögren's Syndrome. , 2014, , 495-510.		3
97	Type I interferon signature may influence the effect of belimumab on immunoglobulin levels, including rheumatoid factor in Sjögren's syndrome. <i>Clinical and Experimental Rheumatology</i> , 2017, 35, 719-720.	0.8	3
98	Vitamin D Deficiency in Primary Sjögren's Syndrome: Association with Clinical Manifestations and Immune Activation Markers. <i>Mediterranean Journal of Rheumatology</i> , 2022, 33, 106.	0.8	3
99	THU0204...ASSOCIATION OF LILRA3 GENE WITH LYMPHOMAGENESIS RISK IN YOUNG SS PATIENTS. , 2019, , .		2
100	Psychological comorbidities associated with subclinical atherosclerosis in Greek patients with primary Sjögren's syndrome: a potential contribution of sleep impairment. <i>Clinical and Experimental Rheumatology</i> , 2018, 36 Suppl 112, 68-72.	0.8	2
101	Milk Fat Globule Epidermal Growth Factor 8 (MFGE8) Gene Variants in Rheumatoid Arthritis and Sjögren's Syndrome. <i>Journal of Clinical Medicine</i> , 2022, 11, 1180.	2.4	2
102	Subclinical atherosclerosis profiles in rheumatoid arthritis and primary Sjögren's syndrome: the impact of BAFF genetic variations. <i>Rheumatology</i> , 2023, 62, 958-968.	1.9	2
103	Treatment of dry eyes in Sjögren's syndrome: the role of autologous blood serum. <i>Expert Opinion on Orphan Drugs</i> , 2013, 1, 445-456.	0.8	1
104	AB0183...THE ROLE OF THE PHOSPHOLIPASE LP-PLA2 ACTIVITY IN SJOGREN'S SYNDROME RELATED LYMPHOMAGENESIS: A NEW SERUM BIOMARKER?. , 2019, , .		1
105	THU0228...EXPRESSION OF APOBEC FAMILY MEMBERS AS REGULATORS OF ENDOGENOUS RETROELEMENTS AND MALIGNANCY IN SYSTEMIC LUPUS ERYTHEMATOSUS AND SJOGREN'S SYNDROME. , 2019, , .		1
106	Type I Interferonopathies: From Pathophysiology to Clinical Expression. , 2019, , 125-145.		1
107	Sjögren's Syndrome. , 2020, , 225-262.		1
108	Polyarthritis and Psoriasiform Skin Lesions following Pembrolizumab Therapy. <i>Mediterranean Journal of Rheumatology</i> , 2021, 32, 367.	0.8	1

#	ARTICLE	IF	CITATIONS
109	Lupus-like disease and progressive multifocal leukoencephalopathy following etanercept treatment: just a coincidence?. <i>Clinical and Experimental Rheumatology</i> , 2022, 40, 671-672.	0.8	1
110	Sjögren's Syndrome. , 2015, , 419-428.		0
111	Etiopathogenesis of Sjögren's Syndrome. <i>Rare Diseases of the Immune System</i> , 2016, , 279-292.	0.1	0
112	07.13...A case of sting-associated vasculopathy with onset in infancy (savi) in a young adult male with a novel tmem173 gene mutation. , 2017, , .		0
113	Drs. Mavragani and Moutsopoulos reply. <i>Journal of Rheumatology</i> , 2020, 47, 158.2-158.	2.0	0
114	A case of antisynthetase syndrome. <i>Clinical Case Reports (discontinued)</i> , 2020, 8, 1586-1587.	0.5	0
115	B-cell Activating Factor Polymorphisms in Rheumatoid Arthritis-Associated Atherosclerosis. <i>Mediterranean Journal of Rheumatology</i> , 2021, 32, 179.	0.8	0
116	Immune Dysfunction and Drug Targets in Autoinflammatory Syndromes. , 2021, , .		0
117	Scleroderma specific autoantibodies and MS-like manifestations: A novel association?. <i>Autoimmunity Reviews</i> , 2021, 20, 102871.	5.8	0
118	Sjögren's Syndrome. , 2014, , 1069-1075.		0
119	The Role of Novel Autoantibodies in the Diagnostic Approach and Prognosis of Patients with Raynaud's Phenomenon. <i>Mediterranean Journal of Rheumatology</i> , 2020, 31, 427.	0.8	0
120	Editorial: Management of Sjögren's Syndrome. <i>Frontiers in Medicine</i> , 2021, 8, 836182.	2.6	0
121	A Training Tool to support the management and diagnosis of Sjögren's syndrome. <i>Clinical and Experimental Rheumatology</i> , 2020, 38 Suppl 126, 174-179.	0.8	0
122	Combined seronegativity in Sjögren's syndrome. <i>Clinical and Experimental Rheumatology</i> , 2021, , .	0.8	0
123	Sjögren's syndrome and lung involvement. <i>Handbook of Systemic Autoimmune Diseases</i> , 2022, , 55-71.	0.1	0
124	Lupus-like disease and progressive multifocal leukoencephalopathy following etanercept treatment: just a coincidence?. <i>Clinical and Experimental Rheumatology</i> , 2021, , .	0.8	0